Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE: WAT) announced the launch of the ACQUITY RDa™ Detector, featuring SmartMS™ technology. This new time-of-flight (TOF) mass spectrometer simplifies the small molecule analysis process across pharmaceutical, academic, food, and forensic applications. The RDa Detector promises high mass accuracy and ease of use, enabling quicker decision-making with robust workflows. Optimized for critical applications, it supports compliance and data integrity. The product is now available worldwide through Waters and its distributors.
Waters Corporation (NYSE:WAT) has partnered with TetraScience to offer the Empower™ Data Science Link, enhancing access to chromatography data for life sciences organizations. This cloud-native technology enables users to export data into third-party analysis tools, accelerating scientific discovery through advanced analytics. The collaboration allows Empower-enabled organizations to leverage distributed data for actionable insights, critical for quality-driven activities.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will speak at the Cowen Healthcare Conference on March 3, 2021, at 2:40 PM EST. Investors interested in the presentation can access the live webcast via the Waters website in the investor relations section. Waters Corporation is a leader in specialty measurement, providing innovations in chromatography, mass spectrometry, and thermal analysis for over 60 years, with a workforce of more than 7,000 employees operating in 35 countries.
Waters Corporation (NYSE:WAT) has launched the ACQUITY PREMIER Solution, a next-generation liquid chromatograph featuring the innovative MaxPeak High Performance Surface (HPS) technology. This breakthrough aims to enhance analytical data quality and reduce the need for costly sample passivation. The ACQUITY PREMIER solution improves analyte recovery, assay reproducibility, and cuts sample-to-results time, specifically for metal-sensitive analytes. Senior VP Ian King highlighted its potential to redefine value in separations science, contributing significantly to drug development and scientific progress.
Waters Corporation (NYSE: WAT) reported fourth quarter 2020 sales of $787 million, a 10% increase from $716 million in Q4 2019. Diluted EPS rose to $3.49 from $3.12. For fiscal 2020, total sales were $2,365 million, a 2% decrease from $2,407 million in 2019. Despite challenges, the company expects 2021 constant-currency sales growth of 5% to 8% and non-GAAP EPS of $9.32 to $9.57. The Board approved an extension of the share repurchase program with $1.5 billion remaining. Full details available in the Investor Relations section.
Waters Corporation (NYSE:WAT) has launched the Otto SPEcialist Positive Pressure Manifold, designed to enhance the reliability of solid phase extraction (SPE) in laboratories. This semi-automated system features 21 CFR Part 11 compliant software that minimizes workflow errors and user variability, promoting reproducible results. The Otto SPEcialist system accommodates various SPE device sizes and provides precise control over sample processing. Unlike complex automated systems, it is user-friendly and requires minimal setup costs, making it an efficient solution for laboratories across pharmaceutical, biopharmaceutical, food and beverage, and environmental sectors.
Waters Corporation (NYSE:WAT) plans to host a live webcast of its Q4 2020 financial results conference call on February 2, 2021, at 8:00 a.m. EST. Investors can access the call on Waters’ website. A replay will be available until February 9, 2021. Waters has been a pioneer in chromatography and mass spectrometry innovations for over 60 years, operating in 35 countries with more than 7,000 employees, contributing to sectors like life sciences and materials analysis.
Waters Corporation (NYSE:WAT) has announced that the Xevo TQ-XS atmospheric pressure gas chromatography mass spectrometry (APGC-MS/MS) platform has been approved by the USEPA for the identification of dioxins and furans in environmental samples. This approval follows a two-year collaboration with SGS AXYS Analytical Services, signifying a significant advancement in testing methods. The APGC-MS/MS method offers a more efficient, cost-effective, and sensitive alternative to traditional testing methods, which often involve complex and expensive instrumentation.
Waters Corporation (NYSE:WAT) announces that Udit Batra, Ph.D., CEO, will address investors at the J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 AM EST. The presentation will be accessible via live webcast through the company's investor relations webpage. As a premier specialty measurement company, Waters has over 60 years of experience in chromatography, mass spectrometry, and thermal analysis, operating in 35 countries with more than 7,000 employees globally.
Waters Corporation (NYSE:WAT) has appointed Dr. Pearl S. Huang, a distinguished executive with extensive scientific and pharmaceutical expertise, as a Director effective January 1, 2021. Dr. Huang currently leads Cygnal Therapeutics and has previously held significant roles at Roche and GSK, co-founding BeiGene. Waters' leadership emphasized that her experience will enhance the company’s growth in the pharma and biopharma sectors. This strategic addition to the board is expected to drive innovation and broaden the company's footprint in pharmaceutical and clinical laboratories globally.